Genmab — September 2020

[E_L]

Now all we need is Lagarde to tell us they now will start buying biotech stocks to stimulate the economy. Specially Danish ones

[gentogen]

The Cami article looks very interesting but it is based on preclinical models so not as such new data

[E_L]

Genmab’s inaugural appearance in Forbes’ annual ranking of the world’s 2000 largest public companies https://twitter.com/Genmab/status/1304057290086125568

[KWC]

Er denne allerede postet ?

[KWC]

Takeda's Ninlaro Stumbles in Latest Multiple Myeloma Trial

Published: Sep 10, 2020

[KWC]

https://www.biospace.com/article/takeda-s-ninlaro-misses-mark-in-multiple-myeloma-trial/?utm_campaign=Daily Article&utm_content=139589453&utm_medium=social&utm_source=facebook&hss_channel=fbp-10530620221

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

God morgen

[Helge_LarsenPI-redaktør]

TA Genmab: https://www.proinvestor.com/index.php?p=debat_1&postid=86703

[bibob]

Sc Dara in AL . https://www.onclive.com/view/fda-approval-sought-for-subcutaneous-daratumumab-in-al-amyloidosis?utm_source=sfmc&utm_medium=email&utm_campaign=9-10-20_EXE-19-OGD0724_OncLiveSS_RCC CC eNews_Cabometyx_NON_US_Send&eKey=

[Sukkeralf]

Without exaggeration, this is the most significant filing in the modern history of therapeutic developments for patients with AL amyloidosis,” Raymond L. Comenzo, MD, director of the John C. Davis Myeloma and Amyloid Program at Tufts Medical Center told OncLive.

[E_L]

the Camidanlumab article referred to yesterday - CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity -
https://jitc.bmj.com/content/8/2/e000860 (preclinical as gentogen correctly noted)

[E_L]

Genmab
@Genmab

We are proud of our antibody platforms. Read an article published in the JCO on DuoBody-CD3×CD20, a #BispecificAntibody created using DuoBody technology with the potential to create novel therapies for lymphoma https://twitter.com/Genmab/status/1304344075747942400

[E_L]

it is a repeat of the ASCO data

[gentogen]

Using health care claims databases, our analysis indicates that the adjusted (unadjusted) prevalence of AL amyloidosis increased significantly from 20.1 (15.5) cases per million in 2007 to 50.1 (40.5) cases per million in 2015, an annual percentage change of 12% (11.9%)

[gentogen]

Extrapolating from these data, there were at least 12 000 adults in the United States living with AL amyloidosis in 2015

[gentogen]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965052/

[gentogen]

So this is very good news for patients

[E_L]

Genmab

annual report p 26 -3,000-4,000 approximate number of new cases diagnosed annually, making AL amyloidosis the most common type of amyloidosis in the U.S - An estimated 16,000 people in the United States suffer from amyloidosis. - 12-15% of multiple myeloma patients develop light chain (AL) amyloidosis.

[E_L]

The problem with amyloidosis is that it is often not recognised immediatley as amyloidosis ; it often comes through other doctors after hearth or renal failure if i understand correctly